Abstract: Purpose Reports of loperamide abuse to achieve euphoric effects have been increasing. In September of 2019, the Food and Drug Administration (FDA) stated manufacturers will limit package sizes of loperamide to reduce inappropriate use. We aim to characterize pharmacist knowledge of loperamide abuse at the point of retail access and determine what pathways pharmacists have throughout the U.S. to limit the sale of loperamide packages when abuse is suspected.
